The CHMP recommendation is for SC Rybrevant in combination with Lazcluze (lazertinib) for the first-line treatment of patients with advanced NSCLC with ... cancer drug Imfinzi (durvalumab) as ...

Imfinzi is the global standard of care in the curative-intent setting of unresectable, stage III NSCLC in patients whose disease has not progressed after chemoradiotherapy. It is also approved for ...

In addition to its indication in LS-SCLC, Imfinzi is the only approved immunotherapy and the global standard of care in the curative-intent setting of unresectable, Stage III NSCLC in patients whose ...

In addition to its indication in LS-SCLC, Imfinzi is the only approved immunotherapy and the global standard of care in the curative-intent setting of unresectable, Stage III NSCLC in patients ...

As part of a broad development programme, Imfinzi is being tested as a single treatment and in combinations with other anti-cancer treatments for patients with SCLC, NSCLC, bladder cancer ...

and Imfinzi (durvalumab) in NHS patients across England and Wales. Tagrisso has been recommended for use as an adjuvant treatment following complete resection in adults with stage 1B to 3A non-small ...

Johnson & Johnson JNJ announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use ...

AstraZeneca’s (AZN) Imfinzi has been recommended for approval in the European Union, EU, as monotherapy for the treatment of adults with limited-stage small cell lung cancer, LS-SCLC ...

FDA 2025 pulmonology drug alerts, including drug approvals/warnings, vaccine approvals, and medical device recalls/updates.

After a setback in a trial of Imfinzi in early non-small cell lung cancer (NSCLC) last year, AstraZeneca has clawed back some ground with a positive result in small-cell lung cancer (SCLC), a less ...